Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Eiger BioPharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare diseases, particularly its lead product, Avexitide, targeting post-bariatric hypoglycemia. The company's unique position in the niche market of rare diseases, combined with its high gross margin of 95.1%, allows it to maintain a competitive edge despite ongoing operational losses.
Eiger generates revenue through the commercialization of its therapeutics, primarily Avexitide, which has shown efficacy in treating post-bariatric hypoglycemia. The company benefits from a high gross margin due to the specialized nature of its products and limited competition in the rare disease space.
FDA approval timelines for Avexitide and other pipeline candidates
Partnership announcements or licensing deals with larger pharmaceutical companies
Clinical trial results and efficacy data
Market adoption rates of Avexitide post-launch
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of alternative therapies for post-bariatric hypoglycemia
Increased competition from larger biotech firms entering the rare disease market
High operational losses leading to liquidity concerns
Dependence on external financing for R&D activities
low - Eiger operates in a niche market with demand driven by specific medical needs rather than general economic conditions.
Moderate - Rising interest rates could increase the cost of capital for Eiger, affecting its ability to fund R&D and operational expenses.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
growth - Investors are likely attracted to the potential for significant upside from successful drug development.
high - The stock has exhibited high volatility, particularly with recent returns showing a 255.6% increase over six months followed by a 32% decline.
